Please assess the completion status of the following clinical trial:

Trial Title: Acrobat Coronary Stent System Effectiveness European Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible for PCI and demonstrating native vessel or vein/arterial graft disease~* symptomatic CAD: either stable angina pectoris (CCS 1, 2, 3 pr 4) or unstable (Braunwald Class 1-3, B-C) or positive functional ischemia study~* Male and post-menopausal female~* Patient provides written informed consent prior to procedure~* Patient willing to comply with protocol~* Acceptable candidate for CABG~* Patient indicated for stenting of one or more de novo stenotic lesions in native coronary arteries or bypass grafts with or without direct stenting~* All target lesions for stenting in single or multi-vessel disease meet all inclusion criteria~* None of the lesions requires stenting with Drug eluting stents~* At least one lesion is visually estimated to be candidate for direct stenting~* All target lesions for stenting have a visually estimatd RVD \>= 2.5 mm and \<= 3.5 mm~* All target lesions for stenting are visually estimated to have LL =\< 20 mm (to cover the lesion with 1 stent)~* All target lesions for stenting visually estimated to have a stenosis \> 50% and \< 99%~* All target lesions for stenting are ACS lesions TIMI flow \>= 1~Exclusion Criteria:~* Currently enrolled in another clinical trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints~* A previous coronary procedure within 30 days~* Any of the target lesion(s) requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.)~* Previous BMS deployment anywhere in the target vessel within the past 6 months~* Any DES deployment anywhere in the target vessel within the past 9 months~* Any previous stent placement within 10 mm (proximal or distal) of the target lesion~* Patient has diabetes mellitus~* Co-morbid condition(s) that could limit the patient's participation or impact the trial~* Documented LVEF \< 30% at the most recent evaluation~* Evidence of AMI within 72 hours of the intended trial procedure and/or with TIMI flow 0~* History of CVA or TIA in the last 6 months~* Leukopenia (\<3.5 x 10\^9/L)~* Neutropenia (\<1000/mm3) \<= 3 days prior to enrollment~* Thrombocytopenia (\<10\^5/mm3) pre-procedure~* Active peptic ulcer or active GI bleeding~* History of bleeding diathesis or coagulopathy or inability to accept blood transfusions~* Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy or sensitivity to contrast media, which cannot be adequately pre-medicated~* Serum creatinine level \> 2.5 mg per dl within 7 days prior to index procedure~* In-stent restenosis~* Patient not able to give consent or read or write or protected by law or under guardianship or deprived of civil rights~* Woman of childbearing age~* Patient not covered by health or social insurance~* Unprotected left main CAD with obstruction \> 50% , not protected by at least one non-obstructed bypass graft to the LAD or left circumflex (LCX) artery or their branches~* Target vessel exhibiting multiple lesions \> 40% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion(s) to be stented based on visual estimate or on-line QCA~* Any target lesion for stenting exhibits an intraluminal thrombus (occupying \> 50% of the true lumen diameter) at any time~* Any target lesion for stenting is excessively tortuous (two bends \> 90° to reach the target lesion)~* Lesion location that is aorto-ostial or within 5 mm of the origin of the LAD or LCX~* Any target lesion for stenting is has side branches \> 2.0 mm in diameter in which bifurcation stenting is planned~* Any target lesion \>20 mm~* Any target lesion totally occluded (CTO)~* Any target lesion has TIMI flow = 0~* Any target lesion with ISR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acrobat (Type: EXPERIMENTAL): Device: PCI with Svelte Acrobat
- Control BMS (Type: ACTIVE_COMPARATOR): Device: PCI with other BMS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues